Retrospective case review of missed opportunities for primary prevention of stroke and TIA in primary care:protocol paper by Moran, G. M. et al.
 
 
Retrospective case review of missed opportunities
for primary prevention of stroke and TIA in primary
care
Turner, Grace; Calvert, Melanie; Feltham, Maxwell; Marshall, Tom
DOI:
10.1136/bmjopen-2014-006622
License:
Creative Commons: Attribution-NonCommercial (CC BY-NC)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Moran, GM, Calvert, M, Feltham, MG & Marshall, T 2014, 'Retrospective case review of missed opportunities for
primary prevention of stroke and TIA in primary care: protocol paper', BMJ open, vol. 4, no. 11, e006622.
https://doi.org/10.1136/bmjopen-2014-006622
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository : checked 4/12/2014
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Retrospective case review of missed
opportunities for primary prevention
of stroke and TIA in primary care:
protocol paper
Grace M Moran, Melanie Calvert, Max G Feltham, Tom Marshall
To cite: Moran GM,
Calvert M, Feltham MG, et al.
Retrospective case review of
missed opportunities for
primary prevention of stroke
and TIA in primary care:
protocol paper. BMJ Open
2014;4:e006622. doi:10.1136/
bmjopen-2014-006622
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2014-
006622).
Received 12 September 2014
Accepted 22 September 2014
Primary Care Clinical
Sciences, University of
Birmingham, Birmingham,
UK
Correspondence to
Grace M Moran;
gxt513@bham.ac.uk
ABSTRACT
Introduction: Stroke is a major health problem and
transient ischaemic attack (TIA) is an important risk factor
for stroke. Primary prevention of stroke and TIA will have
the greatest impact on reducing the burden of these
conditions. Evidence-based guidelines for stroke/TIA
prevention identify individuals eligible for preventative
interventions in primary care. This study will investigate:
(1) the proportion of strokes/TIAs with prior missed
opportunities for prevention in primary care; (2) the
influence of patient characteristics on missed prevention
opportunities and (3) how the proportion of missed
prevention opportunities has changed over time.
Methods and analysis: A retrospective case review will
identify first-ever stroke and patients with TIA between
2000 and 2013 using anonymised electronic medical
records extracted from the health improvement network
(THIN) database. Four categories of missed opportunities
for stroke/TIA prevention will be sought: untreated high
blood pressure in patients eligible for treatment (either
blood pressure ≥160/100 or ≥140/90 mm Hg in patients
at high cardiovascular disease (CVD) risk); patients with
atrial fibrillation with high stroke risk and no anticoagulant
therapy; no lipid modifying drug therapy prescribed in
patients at high CVD risk or with familial
hypercholesterolaemia. The proportion of patients with
each missed opportunity and multiple missed
opportunities will be calculated. Mixed effect logistic
regression will model the relationship between
demographic and patient characteristics and missed
opportunities for care; practice will be included as a
random effect.
Ethics and dissemination: THIN data collection was
approved by the NHS South East Multi-centre Research
Ethics Committee (MREC) in 2003. This study was
approved by the independent scientific review committee
in May 2013. Dissemination of findings has the potential
to change practice, improve the quality of care provided to
patients and ultimately reduce the incidence of strokes and
TIAs. Findings will be published in a peer-reviewed journal
and disseminated at national and international
conferences.
INTRODUCTION
Stroke is one of the leading causes of mortal-
ity and disability in the UK.1 Transient
ischaemic attack (TIA) is characterised by
transient stroke-like symptoms and is an
important risk factor for stroke. Given there
are approximately 110 000 ﬁrst strokes and
46 000 ﬁrst TIAs a year reported in the
UK,1 2 primary prevention is important to
reduce the burden of stroke and TIA.3
Understanding risk factors for stroke and
TIA is important to identify people at high risk
and implement preventative intervention.
Hypertension is arguably the most well-
documented risk factor; a positive and con-
tinuous relationship has been shown between
increasing blood pressure and stroke.4 5 Atrial
ﬁbrillation is associated with a ﬁvefold increase
in stroke risk.6 In addition, evidence suggests
strokes in patients with atrial ﬁbrillation are
associated with greater disability and higher
mortality rates.6 Cholesterol has been identi-
ﬁed as risk factor for stroke; however, the rela-
tionship is not well characterised and is likely
to be complex. Epidemiological studies have
observed an association between lipid levels
and stroke7 but ﬁndings are inconsistent across
studies.8 On the other hand, a systematic
review of 26 studies found a 20% reduction in
strokes with statin therapy compared with
placebo or usual care.9 Other conditions
found to increase stroke risk include diabetes
and cardiovascular disease (CVD).10 In add-
ition, lifestyle factors related to diet, obesity,
physical inactivity, smoking and alcohol intake
have been identiﬁed as risk factors for stroke
and, moreover, have been shown to interact
with other risk factors to exacerbate the risk.
For example, obesity is associated with hyper-
tension and high cholesterol.11
Age is an important risk factor; incidence
and prevalence of stroke and TIA increases
with age2 and stroke risk doubles every
decade over 55 years.12 Male sex has also
been identiﬁed as a risk factor with men
having a higher incidence of stroke com-
pared with women.13 Although the mechan-
ism is not fully understood, increased stroke
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incidence has been observed in south Asian and
Afro-Caribbean ethnic groups.14
A person’s stroke and CVD risk is determined by the
combination of different risk factors. Multivariable CVD
risk equations have been developed to identify high-risk
patients and express risk as a probability over a period of
time.15 Multiple risk equations exist, although they differ
slightly in the risk factors included, the majority include
age, sex, blood pressure, cholesterol, smoking and dia-
betes.16 Patients with atrial ﬁbrillation stroke risk is
increased by independent risk factors.17 Stroke risk algo-
rithms for these patients include the risk factors: age,
congestive heart failure, hypertension, diabetes and pre-
vious stroke or TIA.6
Primary care offers the best opportunity to identify
people at high risk of stroke and TIA and administer
preventative action. Studies have shown that pharmaco-
logical treatments reduce risk by a constant propor-
tion.18 Evidence-based guidelines relevant to stroke
prevention have been developed for hypertension, atrial
ﬁbrillation and lipid modiﬁcation. Hypertension guide-
lines advise antihypertensive drug therapy is initiated in
people with sustained blood pressure ≥160/100 mm Hg
or a lower threshold of ≥140/90 mm Hg for people with
established CVD, diabetes or an estimated CVD risk of
≥20% over 10 years.19 Atrial ﬁbrillation guidelines rec-
ommend patients’ stroke risk is assessed using an algo-
rithm and high-risk patients should be prescribed
anticoagulant therapy.6 Lipid modiﬁcation guidelines
advise lipid lowering drug therapy should be initiated in
people considered high risk as opposed to measuring
blood cholesterol levels. Guidelines regard high risk as
people with established CVD, diabetes or an estimated
CVD risk of ≥20% over 10 years and endorse prescrip-
tion of statins.16
Despite the extensive evidence-based guidelines to
reduce stroke risk, patients who present at hospital with
ﬁrst stroke have been found to have multiple untreated
or undertreated risk factors.20 Furthermore, it has been
found that some general practitioners (GPs) accept
higher blood pressure thresholds than recommended by
the guidelines21 and overestimate the proportion of
their patients with controlled blood pressure.22 Existing
studies of adherence to stroke prevention guidelines are
limited as they use hypothetical questionnaires or retro-
spective interviews, where responses may differ from
actual practice, and often focus on only one risk factor.
Considering the complexity of the risk factors for ﬁrst-
time stroke and TIA, a large-scale UK study using real-
life primary care data to examine the administration of
primary prevention is an important and necessary step
to reduce the burden of strokes and TIAs on the
National Health Service (NHS) and society.
AIMS
The study aims to investigate: (1) the proportion of ﬁrst
strokes and TIAs with prior missed opportunities for
prevention in primary care; (2) the inﬂuence of patient
characteristics on missed prevention opportunities and
(3) how proportions of missed prevention opportunities
have changed over time.
METHODS AND ANALYSIS
Study design
A retrospective case review of patients with a ﬁrst-ever
stroke or TIA.
Data source
Relevant data will be extracted from the health improve-
ment network (THIN), a large database of anonymised
UK electronic primary care records. Data are comprised
of over 500 general practices, include 11.9 million
patients and cover 6% of the UK population.23 The infor-
mation recorded within THIN is comprehensive and
includes demographics, diagnoses, prescriptions, add-
itional health information (eg, lifestyle factors), socio-
economic data and free-text comments. Data are coded
using drug codes which correspond to British National
Formulary (BNF) chapters24 and Read codes (V.2).25
THIN data collection was approved by the NHS South
East Multi-centre Research Ethics Committee (MREC) in
2003.26
Population
Patients with stroke and TIA between 2000 and 2013 will
be identiﬁed and relevant data extracted from the THIN
database. This study will investigate primary prevention
of stroke and TIA; therefore, will comprise of patients
with ﬁrst-ever stroke and TIA. However, as TIA is a risk
factor for stroke, patients will be categorised into three
groups: stroke only, TIA only, stroke with a history of
TIA. To exclude childhood stroke, only patients with a
diagnosis of stroke or TIA over 18 years will be included
in the study. Date of stroke or TIA will be taken as the
index date, and patients must be registered for at least
1 year prior to the index date to allow sufﬁcient time for
risk factor data to be recorded. To ensure data quality,
the index date must occur at least 1 year after the prac-
tice had begun using Vision software, and after the prac-
tice date of acceptable mortality recording, the year
mortality rates for the practice correspond to expected
regional mortality rates.27
Outcomes
Four missed opportunities for primary stroke and TIA
prevention have been deﬁned through consulting rele-
vant guidelines6 16 19 and encompass the risk factors
hypertension, atrial ﬁbrillation and dyslipidaemia. The
missed opportunities will be deﬁned as:
1. Untreated high blood pressure: Patients with an average
of three blood pressure recordings ≥160 mm Hg for
systolic or ≥100 mm Hg for diastolic but no antihy-
pertensive medication has been prescribed.
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2. Untreated moderately high blood pressure and at high CVD
risk: Patients with an average of three blood pressure
recordings ≥140 mm Hg for systolic or ≥90 mm Hg
for diastolic and have a history of coronary heart
disease (CHD), peripheral arterial disease (PAD),
chronic kidney disease (CKD), diabetes mellitus and
over 40 years or an estimated CVD risk of ≥20% over
10 years but no antihypertensive medication has been
prescribed.
3. Atrial ﬁbrillation and at high risk of stroke with no anti-
coagulant therapy prescribed: Patients with atrial ﬁbrilla-
tion and a CHADS2 score ≥1 but no anticoagulant
medication prescribed.
4. Patients at high CVD risk or with familial hypercholesterol-
aemia and no lipid-modifying drug therapy prescribed:
High CVD risk will be deﬁned as having a history of
CHD, PAD, CKD, diabetes mellitus and over 40 years
or an estimated CVD risk of ≥20% over 10 years.
Definition of outcomes and variables
Stroke/TIA
A comprehensive list of stroke and TIA Read codes has
been developed to identify the eligible population (see
online supplementary appendix 1). A systematic search
strategy was conducted to ensure all relevant Read codes
were included:
1. Quality Outcomes Framework (QOF)28 stroke and
TIA Read codes were reviewed for relevance to the
study’s eligibility criteria. To capture ﬁrst stroke and
TIA, Read codes relating to history of stroke or TIA
were removed.
2. To identify additional Read codes not included in
QOF, we conducted a hierarchy screening of QOF
stroke and TIA Read codes and key word searches
using STATAV.12 (College Station, Texas, USA).
3. Literature was searched for additional Read codes
and a clinician was consulted.
Missed opportunities variables
To identify patients with blood pressure ≥160/100 or
≥140/90 mm Hg, the average of the three most recent
systolic and diastolic blood pressure recordings within
3 years prior to the index date will be used. Diagnoses of
atrial ﬁbrillation, CHD, CKD, diabetes mellitus and PAD
will be identiﬁed using QOF Read codes (V.27).28 In
addition, where present, Read codes indicating history
of diagnosis will be used. Similarly, where available, we
have identiﬁed ‘resolved’ Read codes (eg, 212H.00 dia-
betes resolved), which will be used to indicate if the con-
dition resolved before the index date (see online
supplementary appendix 2). Familial hypercholesterol-
aemia is poorly coded in primary care but is associated
with total cholesterol of ≥9 mmol/L.29 Therefore, in
addition to Read codes for familial hypercholesterol-
aemia, total cholesterol of ≥9 mmol/L (most recent
record prior to index date) will be used to indicate
familial hypercholesterolaemia.
A missed opportunity will be identiﬁed if a patient was
eligible for primary prevention drug therapy but was not
on relevant treatment at the time of stroke or TIA. To
determine if patients were on antihypertensive, anti-
coagulant or lipid-modifying drug therapies before their
stroke or TIA, the most recent prescriptions for these
drugs prior to the index date will be extracted.
Prescriptions will be identiﬁed using drug codes corre-
sponding to relevant BNF chapters (V.67) and relevant
Read codes (eg, 66Q..11, anticoagulant monitoring; see
online supplementary appendix 3). In primary care,
90 days is the maximum prescribing length for any treat-
ment. Therefore, a missed opportunity will be recorded
when patients were eligible for treatment but their most
recent prescription was over 90 days from the index date
and consequently were not on treatment at the time of
stroke or TIA. However, prescribing anticoagulant
therapy usually involves referral to an anticoagulant
clinic; to account for this, an additional lag period of
30 days will be allowed for anticoagulant prescribing (ie,
120 days from the index date). The length of the lag
period was determined though consultation with eight
practising GPs.
The Framingham risk equation will be used to calcu-
late CVD risk over 10 years (table 1). This risk equation
was chosen as it can be incorporated within Vision, the
electronic system used by general practices that contrib-
ute to the THIN database. In addition, it was the risk
score recommended by the guidelines during the major-
ity of the study period16 and the equation is freely avail-
able. For consistency, the Framingham CVD risk will be
calculated at the index date for all eligible patients and
in accordance with Vision calculations.30 As recom-
mended by the guidelines, the Framingham CVD risk
will be adjusted for South Asian ethnicity and family
history of premature CHD.16 The CHADS2 score will be
used to determine stroke risk for patients with atrial
Table 1 Variables required for the Framingham
cardiovascular disease risk equation
Variable Criteria
Default
value
Age* 30–74 †
Sex Male/female †
Systolic blood
pressure
Most recent record prior
to index date
†
Total cholesterol Most recent record prior
to index date
6.0
HDL cholesterol Most recent record prior
to index date
Female:
1.4
Male: 1.15
Smoking Yes/no
Diabetes mellitus Yes/no
ECG-LVH Yes/no
*Age at index date.
†Mandatory field.
HDL, high-density lipoprotein; LVH, left ventricular hypertrophy.
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ﬁbrillation (table 2). Similar to the Framingham risk
equation, CHADS2 will be used because it can be incor-
porated within Vision and it will be calculated at the
index date in compliance with Vision calculations.
Predictor variables
Sociodemographic variables will be extracted including
Townsend deprivation quintiles,31 urban rural scores,31
strategic health authority32 and ethnicity. Comorbidities
will be identiﬁed and deﬁned by QOF Read codes
(QOF business rules V.27; see online supplementary
appendix 2).33 To document patients’ contact with
primary care before their stroke or TIA, the number of
consultations in the year prior to the index date and
length of registration will be extracted for each patient.
In addition, Read codes indicating exceptions for initiat-
ing stroke prevention drug therapy will be extracted
including white coat hypertension and contraindications
to prescribing antihypertensive, anticoagulant or lipid-
modifying drugs (eg, 8I3N.00, hypertension treatment
refused; see online supplementary appendix 4).
Predictor variables encompassing modiﬁable and non-
modiﬁable risk factors for stroke and TIA will be
extracted. Non-modiﬁable risk factors include sex and
age at index date, whereas modiﬁable risk factors relate
to lifestyle: body mass index (BMI), smoking and
alcohol intake. GPs initiating lifestyle interventions has
been reported to delay initiation of antihypertensive
drug therapy by up to 12 months;21 therefore, we have
also identiﬁed Read codes indicating lifestyle interven-
tions related to smoking, alcohol intake, diet, exercise
and weight (see online supplementary appendix 5).
Quality checks, missing data and extreme values
Absence of a diagnosis code will be taken to indicate the
diagnosis is not present. For categorical variables (eg,
smoking status), a separate ‘missing’ category will be
created. Extreme values for blood pressure, total and high-
density lipoprotein cholesterol, height and BMI will be
identiﬁed using the ranges seen in the Health Survey for
England statistics as a guide34 and excluded. Incidence of
stroke and TIA diagnoses will be investigated over time to
check for indication of unusual variation which might indi-
cate incorrect clinical coding. If appropriate, a cut-off date
will be introduced for quality of reporting.
Analysis
The primary analysis will calculate the proportion of
strokes and TIAs with missed opportunities for primary
prevention drug therapy. Proportions will be calculated
for each missed opportunity: untreated high blood pres-
sure; untreated moderately high blood pressure and
high CVD risk; atrial ﬁbrillation and high risk of
stroke with no anticoagulant therapy prescribed; high
CVD risk or with familial hypercholesterolaemia and no
lipid-modifying drug therapy prescribed. In addition,
the proportion of patients with two, three or four
missed opportunities will be calculated.
Secondary analysis will comprise of multivariable
logistic regression modelling to predict the effect of
demographic and patient characteristics on missed
opportunities. The logistic regression model will be
mixed effect and include practice as a random effect.
Year of stroke will be included to investigate how missed
opportunities have changed over time. We aim to
develop a model that ﬁts the data well, is biologically
meaningful and can be meaningfully interpreted. To
achieve this, explanatory variables will be entered into
the logistic regression model which have been prespeci-
ﬁed and informed through literature searches and clin-
ical input (table 3). There is compelling evidence from
the literature that age and sex are important predictors
of non-adherence to guidelines in primary care;21 35 36
therefore, these variables will be included in the model
regardless of statistical contribution. Although the other
prespeciﬁed variables have been informed through the
literature and clinical advice, the evidence is limited; for
that reason, a backwards elimination approach will be
adopted to inform model selection. Backwards elimin-
ation will be used as it is favourable over forwards or
stepwise selection.37 Traditionally, a p value of >0.1–0.2 is
used as a criteria to eliminate variables. However, our
sample size is expected to be large and consequently we
will use a p-to-eliminate value of >0.05. Exploratory ana-
lysis will be conducted to explore the relationship of the
effect of consultation frequency in the year prior to the
index date and duration of registration on missed oppor-
tunities for stroke and TIA prevention.
DISCUSSION
This study will quantify the proportion of patients in
whom opportunities to prevent strokes and TIAs were
missed. In addition, it will identify the risk factors with the
highest proportion of untreated patients. The results of
the regression model will be important to provide insight
into patient characteristics that predict missed prevention
opportunities. Dissemination of these ﬁndings to GPs will
raise awareness of patients who are vulnerable to not being
prescribed relevant stroke and TIA prevention pharmaco-
therapy when eligible. Furthermore, the ﬁndings have the
potential to change practice and improve patient care.
The strength of this study is that data are available from
over 500 general practices and reﬂect actual practice.
Table 2 Variables required for the CHADS2 stroke risk
equation for patients with atrial fibrillation
Variable Points
C Congestive heart failure 1
H Hypertension 1
A Age ≥75 years 1
D Diabetes mellitus 1
S2 Prior stroke or TIA 2
TIA, transient ischaemic attack.
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However, the data will be extracted from routinely col-
lected electronic medical records and, therefore, does
not capture the decision-making process which occurs
during a consultation. For instance, patients’ preferences
and GPs knowledge of patient’s adherence to medica-
tion.38 Although our study will include comorbidities in
the regression model and report Read codes which indi-
cate contraindications for medications, there may be
other legitimate reasons for not prescribing stroke pre-
vention drug therapy and patients might decline antihy-
pertensive, anticoagulant or lipid-lowering drug therapy.
Inevitably, there will be missing data and errors in data
entry; however, this is expected to be a small proportion
of the population and we will exclude extreme values and
incorporate missing data as a category in the analysis.
The use of QOF Read codes to identify comorbidities is
likely to result in missing diagnoses that have been
recorded using alternative Read codes. However, the use
of QOF Read codes provides a consistent method to iden-
tify diagnoses and, since being introduced, GPs are incen-
tivised to use QOF Read codes.
In conclusion, this study will offer an insight into
whether stroke and TIA risk factors are being managed
adequately in UK primary care. Primary prevention of
stroke and TIA is important to reduce the burden of
these conditions on the NHS and society. If optimal
rates of prevention are not being delivered in primary
care, dissemination of our ﬁndings will be important
and further research should be conducted to identify
barriers to guideline adherence and intervention(s) to
overcome these.
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